Abstract 474P
Background
We investigated KCNJ11 expression in different glioma tissue subtypes and its use as a predictor of glioma prognosis and sensitivity to temozolomide chemotherapy and determined the value of performance evaluation indicators.
Methods
Data on sex, age, histopathological type, WHO grade, IDH mutation, 1p/19q deletion, survival time, and KCNJ11 mRNA were collected from 516 patients with glioma. Expression levels and other data and uni- and multivariate Cox regression analyses were used to determine prognostic factors for patients with glioma. Data obtained from 603 cases with different glioma subtypes in TCGA database, 284 cases in REMBRANDT, and 264 cases in the United States database of the National Center for Biotechnology Information were verified to correlate KCNJ11 mRNA expression levels with the relationship between different clinical features and overall survival.
Results
KCNJ11 mRNA expression in 516 patients with different glioma subtypes correlated with histopathological type, WHO grade, IDH mutation status, 1p/19q co-deletion status, MGMT methylation, and WHO molecular classification (both P<0.05). Median survival times in the high KCNJ11 mRNA expression group were longer than those in the low expression group (P<0.05). Multivariate Cox regression analysis showed that age, tumor recurrence, WHO classification, IDH mutation, 1p/19q co-deletion, postoperative chemotherapy, and KCNJ11 mRNA expression were independent influencing factors of overall patient survival time. In the TCGA dataset, median overall survival times in the high expression group were longer than those in the low expression group (P<0.05). In the REMBRANDT dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05). In the GSE1101 dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05).
Conclusions
KCNJ11 mRNA expression was related to the degree of tumor malignancy and was an independent factor affecting overall survival time, and overall survival times of patients with high KCNJ11 mRNA expression are longer than those of patients with low KCNJ11 mRNA expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Zhou.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
479P - The candidate novel markers PIV and PILE score to predict survival outcomes and therapeutic response in patients with primary central nervous system lymphoma
Presenter: Ling Duan
Session: Poster session 16
Resources:
Abstract
480P - Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma
Presenter: Ana Jiménez-Ubieto
Session: Poster session 16
481P - Integrating GWAS and transcriptomics prioritizes drug targets for meningioma
Presenter: Wan-Zhe Liao
Session: Poster session 16
482P - The prognostic impact of CDKN2A/B heterozygous deletions in meningioma: Insights of a multicenter analysis
Presenter: Franziska Ippen
Session: Poster session 16
483P - The use of steroids associated with PD1/PDL-1 blockage in patients with brain metastasis: A systematic review and meta-analysis
Presenter: Francisco Cezar Moraes
Session: Poster session 16
484P - EGFR amplification is the potential driver gene that accelerates brain metastases in NSCLC patients
Presenter: Hainan Yang
Session: Poster session 16
485P - A spatio-temporal evolution mathematical model of glioma growth: The influence of cellular and nutrient interactions on the tumor microenvironment
Presenter: Kalysta Borges
Session: Poster session 16
486P - Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
Presenter: Julia Grönros
Session: Poster session 16
487P - 3D-bioprinted co-cultures of glioblastoma and mesenchymal cells indicate a role for perivascular niche cells in shaping the chemotactic tumour microenvironment
Presenter: Radosław Zagożdżon
Session: Poster session 16
488P - ITGA2 promotes glioma cell stemness and progression by activating the AKT pathway
Presenter: Lihui Wang
Session: Poster session 16